Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00473252
Other study ID # BE003
Secondary ID
Status Completed
Phase N/A
First received May 14, 2007
Last updated May 19, 2011
Start date May 2006
Est. completion date July 2009

Study information

Verified date May 2011
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Observational

Clinical Trial Summary

Fungal infections in immunocompromised patients occuring during construction activities in hospitals have repeatedly been reported.

However, the question of a causal relation between construction activities and infections has never been addressed systematically and prospectively.

To answer this question, we will monitor our immunosuppressed patients' health status, as well as fine dust and aspergillus spore contents in the air during a three year construction activity period in our hospital.


Recruitment information / eligibility

Status Completed
Enrollment 340
Est. completion date July 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Kidney transplantation

- Chronic hemodialysis treatment

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland Dept. Nephrology & Hypertension, Univ. Hospital Bern Bern

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

See also
  Status Clinical Trial Phase
Suspended NCT01887457 - Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy Phase 2
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Enrolling by invitation NCT01617759 - Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
Terminated NCT03905447 - The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. Phase 2
Recruiting NCT04744454 - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Completed NCT02715570 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 Phase 1
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Completed NCT04935463 - Mucormycosis in COVID-19
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00037206 - A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Phase 2/Phase 3
Completed NCT04818853 - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Recruiting NCT06135597 - Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Terminated NCT02646800 - Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Phase 4
Completed NCT00854607 - An Observational Study of Fungal Biomarkers (MK-0000-089) N/A
Completed NCT00388167 - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Phase 4
Completed NCT05065658 - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Completed NCT00005912 - Voriconazole to Prevent Systemic Fungal Infections in Children Phase 1
Completed NCT04431804 - THYME AND CARVACROLL Nanoparticle Effect on Fungi